[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "falcon",
    "section": "",
    "text": "Implementation of FDA Safety Tables and Figures\n\n\n\n\n\n\n\n\n\nWhat is falcon?\nThe falcon initiative is an industry collaborative effort under pharmaverse that brings together pharmaceutical companies with the aspiration of building and open-sourcing a catalog of harmonized tables, listings, and graphs (TLGs) in clinical study reporting. Leveraging existing open-source R packages, falcon aims to simplify the process of output review, comparison, and meta-analyses, fostering efficient communication among stakeholders in the pharmaceutical sector while aligning with CDISC’s ARD/ARM effort at the same time. Drawing inspiration from the FDA Standard Safety Tables and Figures Integrated Guide, we develop open-source templates. Future plans entail expanding the catalog of templates through continuous collaboration from participating companies and inviting wider industry to promote harmonization of TLGs for clinical reporting.\n\nGetting Started\nTemplate Library Index \n \n\n\nOur Collaboration Journey\nFAQ\n\nUpcoming Talks & Presentations\n\n\nPHUSE EU Connect 2023 - 5-8 November 2023\nContributors\n\n\n\n\n\n\n\n\nEmily de la Rua\nAbinaya Yogasekaram\n\n\n\n\n\n\n\n\n\nJessica Knizia\nYoshito Koujin\nKorbinian Matthias\n\n\n\n\n\n\n\n\n\nAlex Assuied\n\n\n\n\n\n\n\n\n\nYuye Wang"
  },
  {
    "objectID": "LICENSE.html",
    "href": "LICENSE.html",
    "title": "",
    "section": "",
    "text": "Apache License\nVersion 2.0, January 2004 &lt;http://www.apache.org/licenses/&gt;\n\nTerms and Conditions for use, reproduction, and distribution\n\n1. Definitions\n“License” shall mean the terms and conditions for use, reproduction, and distribution as defined by Sections 1 through 9 of this document.\n“Licensor” shall mean the copyright owner or entity authorized by the copyright owner that is granting the License.\n“Legal Entity” shall mean the union of the acting entity and all other entities that control, are controlled by, or are under common control with that entity. For the purposes of this definition, “control” means (i) the power, direct or indirect, to cause the direction or management of such entity, whether by contract or otherwise, or (ii) ownership of fifty percent (50%) or more of the outstanding shares, or (iii) beneficial ownership of such entity.\n“You” (or “Your”) shall mean an individual or Legal Entity exercising permissions granted by this License.\n“Source” form shall mean the preferred form for making modifications, including but not limited to software source code, documentation source, and configuration files.\n“Object” form shall mean any form resulting from mechanical transformation or translation of a Source form, including but not limited to compiled object code, generated documentation, and conversions to other media types.\n“Work” shall mean the work of authorship, whether in Source or Object form, made available under the License, as indicated by a copyright notice that is included in or attached to the work (an example is provided in the Appendix below).\n“Derivative Works” shall mean any work, whether in Source or Object form, that is based on (or derived from) the Work and for which the editorial revisions, annotations, elaborations, or other modifications represent, as a whole, an original work of authorship. For the purposes of this License, Derivative Works shall not include works that remain separable from, or merely link (or bind by name) to the interfaces of, the Work and Derivative Works thereof.\n“Contribution” shall mean any work of authorship, including the original version of the Work and any modifications or additions to that Work or Derivative Works thereof, that is intentionally submitted to Licensor for inclusion in the Work by the copyright owner or by an individual or Legal Entity authorized to submit on behalf of the copyright owner. For the purposes of this definition, “submitted” means any form of electronic, verbal, or written communication sent to the Licensor or its representatives, including but not limited to communication on electronic mailing lists, source code control systems, and issue tracking systems that are managed by, or on behalf of, the Licensor for the purpose of discussing and improving the Work, but excluding communication that is conspicuously marked or otherwise designated in writing by the copyright owner as “Not a Contribution.”\n“Contributor” shall mean Licensor and any individual or Legal Entity on behalf of whom a Contribution has been received by Licensor and subsequently incorporated within the Work.\n\n\n2. Grant of Copyright License\nSubject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable copyright license to reproduce, prepare Derivative Works of, publicly display, publicly perform, sublicense, and distribute the Work and such Derivative Works in Source or Object form.\n\n\n3. Grant of Patent License\nSubject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable (except as stated in this section) patent license to make, have made, use, offer to sell, sell, import, and otherwise transfer the Work, where such license applies only to those patent claims licensable by such Contributor that are necessarily infringed by their Contribution(s) alone or by combination of their Contribution(s) with the Work to which such Contribution(s) was submitted. If You institute patent litigation against any entity (including a cross-claim or counterclaim in a lawsuit) alleging that the Work or a Contribution incorporated within the Work constitutes direct or contributory patent infringement, then any patent licenses granted to You under this License for that Work shall terminate as of the date such litigation is filed.\n\n\n4. Redistribution\nYou may reproduce and distribute copies of the Work or Derivative Works thereof in any medium, with or without modifications, and in Source or Object form, provided that You meet the following conditions:\n\n(a) You must give any other recipients of the Work or Derivative Works a copy of this License; and\n(b) You must cause any modified files to carry prominent notices stating that You changed the files; and\n(c) You must retain, in the Source form of any Derivative Works that You distribute, all copyright, patent, trademark, and attribution notices from the Source form of the Work, excluding those notices that do not pertain to any part of the Derivative Works; and\n(d) If the Work includes a “NOTICE” text file as part of its distribution, then any Derivative Works that You distribute must include a readable copy of the attribution notices contained within such NOTICE file, excluding those notices that do not pertain to any part of the Derivative Works, in at least one of the following places: within a NOTICE text file distributed as part of the Derivative Works; within the Source form or documentation, if provided along with the Derivative Works; or, within a display generated by the Derivative Works, if and wherever such third-party notices normally appear. The contents of the NOTICE file are for informational purposes only and do not modify the License. You may add Your own attribution notices within Derivative Works that You distribute, alongside or as an addendum to the NOTICE text from the Work, provided that such additional attribution notices cannot be construed as modifying the License.\n\nYou may add Your own copyright statement to Your modifications and may provide additional or different license terms and conditions for use, reproduction, or distribution of Your modifications, or for any such Derivative Works as a whole, provided Your use, reproduction, and distribution of the Work otherwise complies with the conditions stated in this License.\n\n\n5. Submission of Contributions\nUnless You explicitly state otherwise, any Contribution intentionally submitted for inclusion in the Work by You to the Licensor shall be under the terms and conditions of this License, without any additional terms or conditions. Notwithstanding the above, nothing herein shall supersede or modify the terms of any separate license agreement you may have executed with Licensor regarding such Contributions.\n\n\n6. Trademarks\nThis License does not grant permission to use the trade names, trademarks, service marks, or product names of the Licensor, except as required for reasonable and customary use in describing the origin of the Work and reproducing the content of the NOTICE file.\n\n\n7. Disclaimer of Warranty\nUnless required by applicable law or agreed to in writing, Licensor provides the Work (and each Contributor provides its Contributions) on an “AS IS” BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied, including, without limitation, any warranties or conditions of TITLE, NON-INFRINGEMENT, MERCHANTABILITY, or FITNESS FOR A PARTICULAR PURPOSE. You are solely responsible for determining the appropriateness of using or redistributing the Work and assume any risks associated with Your exercise of permissions under this License.\n\n\n8. Limitation of Liability\nIn no event and under no legal theory, whether in tort (including negligence), contract, or otherwise, unless required by applicable law (such as deliberate and grossly negligent acts) or agreed to in writing, shall any Contributor be liable to You for damages, including any direct, indirect, special, incidental, or consequential damages of any character arising as a result of this License or out of the use or inability to use the Work (including but not limited to damages for loss of goodwill, work stoppage, computer failure or malfunction, or any and all other commercial damages or losses), even if such Contributor has been advised of the possibility of such damages.\n\n\n9. Accepting Warranty or Additional Liability\nWhile redistributing the Work or Derivative Works thereof, You may choose to offer, and charge a fee for, acceptance of support, warranty, indemnity, or other liability obligations and/or rights consistent with this License. However, in accepting such obligations, You may act only on Your own behalf and on Your sole responsibility, not on behalf of any other Contributor, and only if You agree to indemnify, defend, and hold each Contributor harmless for any liability incurred by, or claims asserted against, such Contributor by reason of your accepting any such warranty or additional liability.\nEND OF TERMS AND CONDITIONS\n\n\n\nAPPENDIX: How to apply the Apache License to your work\nTo apply the Apache License to your work, attach the following boilerplate notice, with the fields enclosed by brackets [] replaced with your own identifying information. (Don’t include the brackets!) The text should be enclosed in the appropriate comment syntax for the file format. We also recommend that a file or class name and description of purpose be included on the same “printed page” as the copyright notice for easier identification within third-party archives.\nCopyright [yyyy] [name of copyright owner]\n\nLicensed under the Apache License, Version 2.0 (the \"License\");\nyou may not use this file except in compliance with the License.\nYou may obtain a copy of the License at\n\n  http://www.apache.org/licenses/LICENSE-2.0\n\nUnless required by applicable law or agreed to in writing, software\ndistributed under the License is distributed on an \"AS IS\" BASIS,\nWITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.\nSee the License for the specific language governing permissions and\nlimitations under the License."
  },
  {
    "objectID": "quarto/index-templates.html",
    "href": "quarto/index-templates.html",
    "title": "Template Library Index",
    "section": "",
    "text": "FDA Tables\n\nFDA Table 2 – Baseline Demographic and Clinical Characteristics, Safety Population, Pooled Analyses\nFDA Table 5 – Duration of Treatment Exposure, Safety Population, Pooled Analyses\nFDA Table 6 – Overview of Adverse Events, Safety Population, Pooled Analyses\nFDA Table 7 – Deaths, Safety Population, Pooled Analyses\nFDA Table 8 – All Individual Patient Deaths, Safety Population, Pooled Analyses\nFDA Table 9 – Patients With Serious Adverse Events by System Organ Class and Preferred Term, Safety Population, Pooled Analyses\nFDA Table 13 – Patients With Common Adverse Events Occurring at &gt;=X% Frequency, Safety Population, Pooled Analyses\nFDA Table 14 – Patients With Adverse Events by System Organ Class and FDA Medical Query, Safety Population, Pooled Analyses\nFDA Table 20 – Adverse Events of Special Interest Assessment, Safety Population, Pooled Analysis (or Trial X)\nFDA Table 32 – Percentage of Patients With Maximum Diastolic Blood Pressure by Category of Blood Pressure Postbaseline, Safety Population, Pooled Analysis\nFDA Table 33 – Percentage of Patients Meeting Specific Hypotension Levels Postbaseline, Safety Population, Pooled Analysis"
  },
  {
    "objectID": "quarto/about.html",
    "href": "quarto/about.html",
    "title": "About the Project",
    "section": "",
    "text": "The falcon project is a product of industry collaboration to encourage the development of shared code, expertise, knowledge, and products.\nIn the near future, the goal is to develop functionality to create regulatory reporting tables suitable for FDA filing. The long-term objective of this collaboration is to develop an R package that can be used industry wide - developing a cross-industry standard and reducing manual work from a reporting perspective."
  },
  {
    "objectID": "quarto/about.html#our-collaboration-journey",
    "href": "quarto/about.html#our-collaboration-journey",
    "title": "About the Project",
    "section": "Our Collaboration Journey",
    "text": "Our Collaboration Journey\nCurrent collaborators are from Roche, Sanofi, Boehringer Ingelheim, and Moderna. Developers are connected via Slack and GitHub for the creation of shared solutions using publicly available analysis packages for R. Developers are invited to browse the falcon project repository and related packages for insight into our template designs.\n\nJoining as a Collaborator\nAs always we invite further collaboration and welcome additional companies to join the falcon initiative and contribute to the project. Please feel free to contact any of the repository maintainers for more information and check out the section below for more information on joining the project as a developer.\n\nInformation for Developers\nAs a pharmaverse collaboration, we invite any interested developers to join the falcon team and contribute to template development. To onboard as a developer, please reach out to one of the falcon Product Owners (Vincent Shen, Freeman Wang, Juergen Boehl, Lian Lin, or Clara Beck) to receive access to the falcon GitHub repository.\nTasks are assigned and prioritized via issues on our GitHub project board and worked on in development branches. Members of the team will review each other’s code and make suggestions before new functions and features are incorporated into the package.\nWe encourage the smart developer to familiarize themselves with the following packages as they contain functions leveraged by falcon for table creation:\n\nrtables: Table creation\ntern: Clinical trials analysis functions\nscda.2022: Example synthetic CDISC datasets\nscda: Loading synthetic CDISC data"
  },
  {
    "objectID": "quarto/getting_started.html",
    "href": "quarto/getting_started.html",
    "title": "Getting Started",
    "section": "",
    "text": "Environment Setup and Package Installation\nEnvironment Setup\nPlease ensure that R version 3.6 or higher is installed on your computer. This is required to install the falcon package and its dependencies. You can check your current version of R by running sessionInfo() within the R console.\nInstalling Package Dependencies\nThe falcon package requires several packages available on CRAN.\nTo use the falcon package, ensure you have these necessary package dependencies installed by running the following code:\n\nif (!require(\"formatters\")) install.packages(\"formatters\")\nif (!require(\"rtables\")) install.packages(\"rtables\")\nif (!require(\"rlistings\")) install.packages(\"rlistings\")\nif (!require(\"remotes\")) install.packages(\"remotes\")\nif (!require(\"tern\")) install.packages(\"tern\")\n\nOptionally, to run the examples provided within the falcon package and on this site you can also install the synthetic CDISC data packages from GitHub, which contain the example datasets, by running the following:\n\nif (!require(\"scda\")) remotes::install_github(\"insightsengineering/scda@*release\")\nif (!require(\"scda.2022\")) remotes::install_github(\"insightsengineering/scda.2022@*release\")\n\nFor more information on these packages, see the Additional Resources section below.\nInstalling the falcon Package\nTo install the falcon package, run the following line of code:\n\nif (!require(\"falcon\")) remotes::install_github(\"pharmaverse/falcon\")\n\nLoading Data\nThe table functions provided by falcon are designed to work with any datasets which adhere to CDISC standards. If you have access to CDISC data, load this into your R environment as usual to use when generating tables.\nIf you do not have access to CDISC data, or want to run the examples provided within the package, you can use the scda package to load a selection of datasets stored in the scda.2022 package containing example synthetic CDISC data. Datasets can be loaded using the synthetic_cdisc_dataset() function from scda. Specify the archive_name parameter, setting archive_name as \"latest\" for the most recent version, or setting another version if desired (see the list of all available versions by running scda::ls_synthetic_cdisc_data()). The dataset_name parameter must also be specified with the name of the desired dataset in lowercase, e.g. dataset_name = \"adsl\". This data is loaded in where necessary as part of the provided examples.\nTemplate Navigation\nA list of all templates currently available in falcon is provided in the Template Library Index, with tables designed based on the FDA Standard Safety Tables and Figures: Integrated Guide.\nEach template provided is associated with a function available within the falcon package, and contains 4 sections:\n\n\nSpec. Screenshot: This tab provides a screenshot of the given table coming from the FDA Standard Safety Table and Figures document.\n\n\n\n\n\n\n\nTable: This tab displays the output table corresponding to the screenshot in the previous tab, generated using the associated falcon table function. You can expect a similar output table when using the table function with your own data, depending on pre-processing and the customizations that you apply via the table function parameters.\n\n\n\n\n\n\n\nTable Setup: This tab provides the code used to generate the example table displayed in the previous tab, including the loading of necessary libraries and example datasets, and any pre-processing steps applied prior to generating the table.\n\n\n\n\n\n\n\nFunction Details: This tab includes details on the table-generating function used for this template. Table functions use the naming convention make_table_XX() where XX is the table number taken from the FDA Standard Safety Table and Figures document (preceded by a 0 if the number is a single digit). Any required variables for the input datasets are listed along with a description of all function arguments. This information is mirrored by the function’s help page accessible within R (i.e. ?make_table_XX).\n\n\n\n\n\n          A link to the function’s source code can be found at the bottom of the page in this tab:\n\n\n\n\nCreating Tables\nThere are many table-generating functions available within the falcon package, each of which is used to generate a different FDA standard safety table using R. These functions create rtables table objects which can then be further customized, paginated, etc. if required using functions from the rtables package.\nUsing the Table Functions\nTo use the table functions you will need to load the falcon package and then call the appropriate table function. For example, to create FDA Safety Table 2, you can run the following code:\n\nlibrary(dplyr)\nlibrary(falcon)\n\n# Data pre-processing - ensure all necessary variables are present in the data\nadsl &lt;- scda::synthetic_cdisc_dataset(\"latest\", \"adsl\") %&gt;%\n  dplyr::mutate(AGEGR1 = as.factor(dplyr::case_when(\n    AGE &gt;= 17 & AGE &lt; 65 ~ \"&gt;=17 to &lt;65\",\n    AGE &gt;= 65 ~ \"&gt;=65\",\n    AGE &gt;= 65 & AGE &lt; 75 ~ \"&gt;=65 to &lt;75\",\n    AGE &gt;= 75 ~ \"&gt;=75\"\n  )) %&gt;% formatters::with_label(\"Age Group, years\")) %&gt;%\n  formatters::var_relabel(AGE = \"Age, years\")\n\n# Create table\ntbl &lt;- make_table_02(df = adsl)\ntbl\n\n                                                  A: Drug X            B: Placebo         C: Combination      Total Population \nCharacteristic                                     (N=134)              (N=134)              (N=132)              (N=400)      \n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nSex                                                                                                                            \n  F                                                79 (59%)            82 (61.2%)            70 (53%)           231 (57.8%)    \n  M                                                55 (41%)            52 (38.8%)            62 (47%)           169 (42.2%)    \nAge, years                                                                                                                     \n  Mean (SD)                                       33.8 (6.6)           35.4 (7.9)           35.4 (7.7)           34.9 (7.4)    \n  Median (Min - Max)                          33.0 (21.0 - 50.0)   35.0 (21.0 - 62.0)   35.0 (20.0 - 69.0)   34.0 (20.0 - 69.0)\nAge Group, years                                                                                                               \n  &gt;=17 to &lt;65                                     134 (100%)           134 (100%)          131 (99.2%)          399 (99.8%)    \n  &gt;=65                                                0                    0                 1 (0.8%)             1 (0.2%)     \nRace                                                                                                                           \n  ASIAN                                           68 (50.7%)            67 (50%)            73 (55.3%)           208 (52%)     \n  BLACK OR AFRICAN AMERICAN                       31 (23.1%)           28 (20.9%)           32 (24.2%)           91 (22.8%)    \n  WHITE                                           27 (20.1%)           26 (19.4%)           21 (15.9%)           74 (18.5%)    \n  AMERICAN INDIAN OR ALASKA NATIVE                  8 (6%)             11 (8.2%)             6 (4.5%)            25 (6.2%)     \n  MULTIPLE                                            0                 1 (0.7%)                0                 1 (0.2%)     \n  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER           0                 1 (0.7%)                0                 1 (0.2%)     \nEthnicity                                                                                                                      \n  NOT REPORTED                                     6 (4.5%)            10 (7.5%)            11 (8.3%)            27 (6.8%)     \n  HISPANIC OR LATINO                              15 (11.2%)           18 (13.4%)           15 (11.4%)            48 (12%)     \n  NOT HISPANIC OR LATINO                         104 (77.6%)          103 (76.9%)          101 (76.5%)           308 (77%)     \n  UNKNOWN                                          9 (6.7%)             3 (2.2%)             5 (3.8%)            17 (4.2%)     \nCountry                                                                                                                        \n  CHN                                             74 (55.2%)           81 (60.4%)           64 (48.5%)          219 (54.8%)    \n  USA                                             10 (7.5%)            13 (9.7%)            17 (12.9%)            40 (10%)     \n  BRA                                             13 (9.7%)             7 (5.2%)            10 (7.6%)            30 (7.5%)     \n  PAK                                              12 (9%)              9 (6.7%)            10 (7.6%)            31 (7.8%)     \n  NGA                                               8 (6%)              7 (5.2%)            11 (8.3%)            26 (6.5%)     \n  RUS                                              5 (3.7%)              8 (6%)              6 (4.5%)            19 (4.8%)     \n  JPN                                              5 (3.7%)              4 (3%)              9 (6.8%)            18 (4.5%)     \n  GBR                                               4 (3%)              3 (2.2%)             2 (1.5%)             9 (2.2%)     \n  CAN                                              3 (2.2%)             2 (1.5%)             3 (2.3%)              8 (2%)      \n\n\nThe above table is created using the default settings. You can customize tables by specifying function parameter values to set input data, variables to include in the table, table annotations, etc.\nTable Customization\nEach template takes several arguments that can be set to generate a table that meets your requirements. A brief overview of the parameters for each template is provided in the Function Details section of each table template page (see the Function Details section above) and the function’s help page within R (i.e. ?make_table_XX), with many of these parameters being standard across table functions.\nTo customize the output table, you can modify the values of these arguments as per your requirements. For example, table 2 can be customized as follows:\n\nadvs &lt;- scda::synthetic_cdisc_dataset(\"latest\", \"advs\") %&gt;%\n  dplyr::filter(AVISIT == \"BASELINE\", VSTESTCD == \"TEMP\") %&gt;%\n  dplyr::select(\"USUBJID\", \"AVAL\")\n\nanl &lt;- dplyr::left_join(adsl, advs, by = \"USUBJID\") %&gt;% tern::df_explicit_na()\n\ntbl &lt;- make_table_02(\n  df = anl,\n  vars = c(\"SEX\", \"AGE\", \"RACE\", \"COUNTRY\", \"AVAL\"),\n  lbl_vars = c(\"Sex\", \"Age, years\", \"Race\", \"Country of Participation\", \"Baseline Temperature (C)\"),\n  lbl_overall = \"Total\\nPopulation\",\n  na_rm = TRUE,\n  annotations = list(\n    title = \"Table 2. Baseline Demographic and Clinical Characteristics Safety Population, Pooled Analyses\",\n    main_footer = \"Source: [include Applicant source, datasets and/or software tools used].\",\n    prov_footer = paste(\n      \"Abbreviations: N, number of patients in treatment arm;\",\n      \"n, number of patients with given characteristic; SD, standard deviation\"\n    )\n  )\n)\ntbl\n\nTable 2. Baseline Demographic and Clinical Characteristics Safety Population, Pooled Analyses\n\n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nCharacteristic                                                                                                     Total       \n                                                  A: Drug X            B: Placebo         C: Combination         Population    \n                                                   (N=134)              (N=134)              (N=132)              (N=400)      \n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nSex                                                                                                                            \n  F                                                79 (59%)            82 (61.2%)            70 (53%)           231 (57.8%)    \n  M                                                55 (41%)            52 (38.8%)            62 (47%)           169 (42.2%)    \nAge, years                                                                                                                     \n  Mean (SD)                                       33.8 (6.6)           35.4 (7.9)           35.4 (7.7)           34.9 (7.4)    \n  Median (Min - Max)                          33.0 (21.0 - 50.0)   35.0 (21.0 - 62.0)   35.0 (20.0 - 69.0)   34.0 (20.0 - 69.0)\nRace                                                                                                                           \n  ASIAN                                           68 (50.7%)            67 (50%)            73 (55.3%)           208 (52%)     \n  BLACK OR AFRICAN AMERICAN                       31 (23.1%)           28 (20.9%)           32 (24.2%)           91 (22.8%)    \n  WHITE                                           27 (20.1%)           26 (19.4%)           21 (15.9%)           74 (18.5%)    \n  AMERICAN INDIAN OR ALASKA NATIVE                  8 (6%)             11 (8.2%)             6 (4.5%)            25 (6.2%)     \n  MULTIPLE                                            0                 1 (0.7%)                0                 1 (0.2%)     \n  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER           0                 1 (0.7%)                0                 1 (0.2%)     \nCountry of Participation                                                                                                       \n  CHN                                             74 (55.2%)           81 (60.4%)           64 (48.5%)          219 (54.8%)    \n  USA                                             10 (7.5%)            13 (9.7%)            17 (12.9%)            40 (10%)     \n  BRA                                             13 (9.7%)             7 (5.2%)            10 (7.6%)            30 (7.5%)     \n  PAK                                              12 (9%)              9 (6.7%)            10 (7.6%)            31 (7.8%)     \n  NGA                                               8 (6%)              7 (5.2%)            11 (8.3%)            26 (6.5%)     \n  RUS                                              5 (3.7%)              8 (6%)              6 (4.5%)            19 (4.8%)     \n  JPN                                              5 (3.7%)              4 (3%)              9 (6.8%)            18 (4.5%)     \n  GBR                                               4 (3%)              3 (2.2%)             2 (1.5%)             9 (2.2%)     \n  CAN                                              3 (2.2%)             2 (1.5%)             3 (2.3%)              8 (2%)      \nBaseline Temperature (C)                                                                                                       \n  Mean (SD)                                       49.7 (8.3)           50.9 (7.4)           49.1 (8.2)           49.9 (8.0)    \n  Median (Min - Max)                          50.4 (29.0 - 69.1)   51.5 (30.7 - 67.7)   48.7 (20.6 - 70.5)   50.3 (20.6 - 70.5)\n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\n\nSource: [include Applicant source, datasets and/or software tools used].\n\nAbbreviations: N, number of patients in treatment arm; n, number of patients with given characteristic; SD, standard deviation\n\n\nNote that the prune_0 argument can be set to specify whether all-zero rows should be included in a table. For example, see that the demographics table below includes rows for OTHER and UNKNOWN for which all values are zero, whereas these two rows were excluded from the previous tables (prune_0 defaults to TRUE in make_table_02()).\n\nmake_table_02(df = anl, vars = \"RACE\", prune_0 = FALSE)\n\n                                              A: Drug X    B: Placebo   C: Combination   Total Population\nCharacteristic                                 (N=134)      (N=134)        (N=132)           (N=400)     \n—————————————————————————————————————————————————————————————————————————————————————————————————————————\nRace                                                                                                     \n  ASIAN                                       68 (50.7%)    67 (50%)      73 (55.3%)        208 (52%)    \n  BLACK OR AFRICAN AMERICAN                   31 (23.1%)   28 (20.9%)     32 (24.2%)        91 (22.8%)   \n  WHITE                                       27 (20.1%)   26 (19.4%)     21 (15.9%)        74 (18.5%)   \n  AMERICAN INDIAN OR ALASKA NATIVE              8 (6%)     11 (8.2%)       6 (4.5%)         25 (6.2%)    \n  MULTIPLE                                        0         1 (0.7%)          0              1 (0.2%)    \n  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER       0         1 (0.7%)          0              1 (0.2%)    \n  OTHER                                           0            0              0                 0        \n  UNKNOWN                                         0            0              0                 0        \n\n\nFeature Requests\nIf you would like to request the addition of a new feature to a pre-existing function within falcon, or would like a specific table template to be added, please file an issue on GitHub here or reach out to the falcon team directly via our Slack channel here.\nYou can access the source code for all currently available functions in the falcon GitHub repository here.\nAdditional Resources\nSee the following packages used by falcon for more information:\n\n\nrtables: Table creation\n\nrlistings: Listing creation\n\ntern: Clinical trials analysis functions\n\nformatters: Additional rendering formatting\n\nscda.2022: Example synthetic CDISC datasets (required for examples only)\n\nscda: Loading synthetic CDISC data (required for examples only)"
  },
  {
    "objectID": "quarto/table-templates/template-table_08.html",
    "href": "quarto/table-templates/template-table_08.html",
    "title": "FDA Table 8",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                                             Dosing    Study           Cause of Death                              \n                                          Age/              Duration   Day of              MedDRA                 Cause of Death   \n  Study Arm           Patient ID         Gender   Dosage     (Days)    Death           Preferred Term              Verbatim Term   \n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nA: Drug X        AB12345-BRA-1-id-42     36/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-1-id-93     34/F     6720 mg   37         658              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-BRA-11-id-345   37/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-11-id-397   38/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-13-id-177   24/M     4800 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-15-id-36    38/F     7200 mg   37         813           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-BRA-2-id-296    44/F     4800 mg   37         NA                    NA                         NA         \n                 AB12345-CAN-11-id-139   31/M     6000 mg   37         564              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-CHN-1-id-123    27/F     5280 mg   37         751           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-1-id-133    25/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-235    39/M     5520 mg   37         969              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-CHN-1-id-275    27/M     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-277    41/M     8160 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-315    32/M     6480 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-316    25/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-329    48/M     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-47     25/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-53     48/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-69     32/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-71     33/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-116   30/M     8880 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-124   41/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-132   30/F     6000 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-153   41/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-167   28/F     4800 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-256   23/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-354   42/F     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-356   28/F     8160 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-392   39/M     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-12-id-266   32/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-12-id-396   25/F     8880 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-1     27/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-161   33/F     6480 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-168   39/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-15-id-399   33/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-17-id-182   37/M     7680 mg   37         903            LOST TO FOLLOW UP                OTHER       \n                 AB12345-CHN-17-id-309   36/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-17-id-92    29/M     5520 mg   37         721            LOST TO FOLLOW UP                OTHER       \n                 AB12345-CHN-18-id-170   31/M     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-22     29/M     8400 mg   38         409                 MISSING                     OTHER       \n                 AB12345-CHN-2-id-223    29/F     5760 mg   37         469           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-2-id-272    41/F     4320 mg   37         775           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-2-id-274    40/F     5520 mg   37         892                 SUICIDE                     OTHER       \n                 AB12345-CHN-2-id-284    36/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-286    30/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-367    40/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-395    28/M     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-3-id-271    24/F     4320 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-3-id-281    41/M     4560 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-4-id-335    33/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-4-id-73     24/F     7920 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-5-id-108    28/F     7440 mg   37         936                 MISSING                     OTHER       \n                 AB12345-CHN-5-id-273    34/F     6240 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-5-id-348    37/M     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-6-id-30     29/M     5280 mg   37         579      Post-study reporting of death          OTHER       \n                 AB12345-CHN-8-id-205    34/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-9-id-374    31/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-GBR-1-id-319    36/F     8160 mg   37         533              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-JPN-18-id-189   48/M     7920 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-5-id-326    34/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-388    39/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-46     28/M     6480 mg   37         698           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-NGA-11-id-41    29/M     8160 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-2-id-353    28/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-148    46/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-79     37/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-11-id-187   32/F     6240 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-12-id-328   21/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-13-id-251   32/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-1-id-52     40/F     6960 mg   37         1070          DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-RUS-13-id-70    39/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-6-id-77     26/F     5760 mg   37         495              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-USA-11-id-32    24/F     7200 mg   38         NA                    NA                         NA         \n                 AB12345-USA-11-id-339   39/F     5280 mg   37         878                 UNKNOWN                     OTHER       \n                 AB12345-USA-3-id-282    38/M     4800 mg   37         NA                    NA                         NA         \n                 AB12345-USA-9-id-130    40/M     5520 mg   37         NA                    NA                         NA         \nB: Placebo       AB12345-BRA-1-id-236    32/M     6480 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-1-id-65     25/F     9120 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-12-id-59    36/M     6480 mg   38         NA                    NA                         NA         \n                 AB12345-BRA-4-id-383    30/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-CAN-1-id-341    43/F     5520 mg   37         1014                SUICIDE                     OTHER       \n                 AB12345-CAN-4-id-331    34/F     6480 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-107    41/M     6240 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-156    32/F     6000 mg   37         543                 SUICIDE                     OTHER       \n                 AB12345-CHN-1-id-186    27/M     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-197    31/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-212    30/F     5040 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-33     31/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-346    21/M     7920 mg   37         835              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-CHN-1-id-400    26/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-86     31/F     8640 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-97     39/F     4080 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-174   41/M     4320 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-220   26/F     4560 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-24    46/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-247   30/M     4560 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-278   47/F     6480 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-289   40/F     4800 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-291   50/M     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-317   38/F     6240 mg   38         658           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-11-id-318   42/F     7920 mg   37         911           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-11-id-358   32/F     4560 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-362   39/F     6240 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-364   48/F     4800 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-54    26/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-90    37/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-12-id-294   35/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-12-id-322   37/M     7920 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-13-id-102   37/M     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-13-id-19    30/F     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-13-id-239   58/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-13-id-304   29/F     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-305   28/F     5760 mg   37         406      Post-study reporting of death          OTHER       \n                 AB12345-CHN-16-id-323   51/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-17-id-48    32/F     6000 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-118    36/F     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-332    31/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-34     48/M     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-3-id-333    30/F     8160 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-4-id-122    23/M     8160 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-5-id-231    37/F     4800 mg   37         470              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-CHN-5-id-338    37/F     7920 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-6-id-385    40/F     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-7-id-126    27/M     7920 mg   37         1067             ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-CHN-7-id-202    44/F     9120 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-7-id-267    40/M     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-9-id-11     28/F     5280 mg   37         399                 UNKNOWN                     OTHER       \n                 AB12345-CHN-9-id-147    26/F     6240 mg   37         NA                    NA                         NA         \n                 AB12345-GBR-17-id-211   62/M     5760 mg   37         456           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-GBR-6-id-111    30/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-1-id-21     29/F     7440 mg   38         NA                    NA                         NA         \n                 AB12345-JPN-14-id-194   28/F     5040 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-325    28/F     5760 mg   37         936           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-NGA-2-id-308    26/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-112    44/M     4080 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-169    29/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-17     33/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-5-id-29     58/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-138    36/M     8160 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-261    32/F     4080 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-269    35/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-394    46/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-USA-11-id-157   50/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-USA-12-id-152   29/F     6240 mg   37         NA                    NA                         NA         \n                 AB12345-USA-12-id-226   30/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-USA-4-id-190    53/M     4560 mg   37         NA                    NA                         NA         \nC: Combination   AB12345-BRA-1-id-141    35/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-1-id-265    25/M     6000 mg   37         873                 SUICIDE                     OTHER       \n                 AB12345-BRA-11-id-321   33/F     9360 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-11-id-9     40/M     7200 mg   37         1091          DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-BRA-4-id-368    46/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-BRA-5-id-234    32/M     4800 mg   37         NA                    NA                         NA         \n                 AB12345-CAN-4-id-324    32/M     6240 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-181    47/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-208    28/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-233    36/F     7680 mg   37         407                 MISSING                     OTHER       \n                 AB12345-CHN-1-id-279    33/M     7920 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-312    34/F     5280 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-347    33/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-376    41/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-64     34/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-74     23/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-1-id-78     44/F     8160 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-113   38/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-146   28/F     5040 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-158   24/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-184   38/F     8400 mg   37         1030          DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-11-id-192   35/F     8640 mg   37         808           DISEASE PROGRESSION        PROGRESSIVE DISEASE\n                 AB12345-CHN-11-id-2     37/F     8880 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-298   31/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-11-id-63    30/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-143   36/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-375   32/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-14-id-56    25/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-15-id-262   35/M     7680 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-15-id-297   31/M     8880 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-16-id-352   28/M     6480 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-16-id-381   45/M     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-17-id-31    35/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-17-id-84    40/F     4560 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-18-id-106   30/F     5040 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-292    32/F     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-342    32/M     6000 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-2-id-98     48/M     8400 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-3-id-155    35/F     6000 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-3-id-259    27/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-4-id-115    38/M     5760 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-5-id-221    40/F     6720 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-5-id-83     44/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-CHN-7-id-290    33/M     6000 mg   37         NA                    NA                         NA         \n                 AB12345-GBR-11-id-390   69/M     6000 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-1-id-7      54/F     8880 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-11-id-135   37/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-11-id-373   45/M     7440 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-12-id-219   37/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-JPN-17-id-393   26/M     7920 mg   37         652              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-JPN-5-id-252    31/F     4800 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-198    32/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-357    41/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-43     37/M     6720 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-1-id-96     28/M     5760 mg   38         NA                    NA                         NA         \n                 AB12345-NGA-11-id-173   24/F     6000 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-11-id-334   20/M     5280 mg   37         NA                    NA                         NA         \n                 AB12345-NGA-11-id-35    32/M     7440 mg   37         925              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-NGA-4-id-215    40/F     8880 mg   37         648              ADVERSE EVENT              ADVERSE EVENT   \n                 AB12345-PAK-1-id-125    49/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-1-id-95     28/F     6240 mg   37         1028     Post-study reporting of death          OTHER       \n                 AB12345-PAK-2-id-188    23/F     7200 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-2-id-191    38/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-PAK-5-id-20     40/M     6960 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-3-id-378    30/F     7440 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-4-id-6      44/F     4320 mg   37         NA                    NA                         NA         \n                 AB12345-RUS-7-id-243    27/F     8400 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-137    29/M     5040 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-242    30/F     5760 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-254    28/F     5520 mg   37         NA                    NA                         NA         \n                 AB12345-USA-1-id-295    30/F     5280 mg   37         NA                    NA                         NA         \n                 AB12345-USA-12-id-140   32/F     7680 mg   37         NA                    NA                         NA         \n                 AB12345-USA-19-id-58    47/M     5520 mg   37         NA                    NA                         NA         \n                 AB12345-USA-2-id-110    35/F     7920 mg   37         NA                    NA                         NA         \n                 AB12345-USA-8-id-206    34/F     6240 mg   37         NA                    NA                         NA         \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\nadex &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adex\")\n\n# Output Table\nmake_table_08(adae = adae, adex = adex)\n\n\n\nmake_table_08()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, AGE, SEX, AESDTH, DTHADY, and the variables specified by dth_vars and arm_var.\n\nadex (if specified): SAFFL, USUBJID, PARAMCD, TRTSDT, TRTEDT, AVAL, and AVALU.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nadex\n(data.frame) Dataset (typically ADEX) required to build table.\nNo default\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\ndth_var\n(vector of character) additional death variables from adae to include in the table.\nc(\"DTHCAUS\", \"DTHCAT\")\n\n\nlbl_dth_vars\n(vector of character) labels corresponding to variables in dth_vars to print in the table. Labels should be ordered according to the order of variables in dth_vars.\nc(\"Cause of Death\\nMedDRA\\nPreferred Term\", \"Cause of Death\\nVerbatim Term\")\n\n\nna_level\n(character) string to represent missing values.\n\"NA\"\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_14.html",
    "href": "quarto/table-templates/template-table_14.html",
    "title": "FDA Table 14",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\nBody System or Organ Class                    BROAD                                      NARROW                 \n  FMQ                        A: Drug X    B: Placebo   C: Combination   A: Drug X    B: Placebo   C: Combination\n                              (N=119)      (N=139)        (N=141)        (N=490)      (N=483)        (N=562)    \n————————————————————————————————————————————————————————————————————————————————————————————————————————————————\ncl A.1                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI       0            0              0              0            0              0       \n  &lt;Missing&gt;                      0            0              0          78 (15.9%)   75 (15.5%)     89 (15.8%)  \ncl B.1                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI       0            0              0              0            0              0       \n  &lt;Missing&gt;                      0            0              0          47 (9.6%)    49 (10.1%)     43 (7.7%)   \ncl B.2                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI   48 (40.3%)   54 (38.8%)     51 (36.2%)         0            0              0       \n  &lt;Missing&gt;                      0            0              0          49 (10.0%)   44 (9.1%)      52 (9.3%)   \ncl C.1                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI   43 (36.1%)   46 (33.1%)     43 (30.5%)         0            0              0       \n  &lt;Missing&gt;                      0            0              0              0            0              0       \ncl C.2                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI       0            0              0              0            0              0       \n  &lt;Missing&gt;                      0            0              0          35 (7.1%)    48 (9.9%)      55 (9.8%)   \ncl D.1                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI       0            0              0              0            0              0       \n  &lt;Missing&gt;                      0            0              0          79 (16.1%)   67 (13.9%)     80 (14.2%)  \ncl D.2                                                                                                          \n  C.1.1.1.3/B.2.2.3.1 AESI       0            0              0              0            0              0       \n  &lt;Missing&gt;                      0            0              0          47 (9.6%)    58 (12.0%)     57 (10.1%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Pre-Processing - Ensure required variables FMQ01SC and FMQ01NAM exist in adae\nadae &lt;- dplyr::rename(adae, FMQ01SC = SMQ01SC, FMQ01NAM = SMQ01NAM)\nlevels(adae$FMQ01SC) &lt;- c(\"BROAD\", \"NARROW\")\nadae$FMQ01SC[is.na(adae$FMQ01SC)] &lt;- \"NARROW\"\n\n# Output Table\nmake_table_14(adae = adae)\n\n\n\nmake_table_14()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, AEBODSYS, and the variables specified by arm_var, fmqsc_var, and fmqnam_var.\n\nalt_counts_df (if specified): SAFFL and USUBJID.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nfmqsc_var\n(character) FMQ scope variable to use in table.\n\"FMQ01SC\"\n\n\nfmqnam_var\n(character) FMQ reference name variable to use in table.\n\"FMQ01NAM\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nFALSE\n\n\nna_level\n(character) string to represent missing values.\n\"&lt;Missing&gt;\"\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_33.html",
    "href": "quarto/table-templates/template-table_33.html",
    "title": "FDA Table 33",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\nBlood Pressure   A: Drug X    B: Placebo   C: Combination\n(Pa)              (N=134)      (N=134)        (N=132)    \n—————————————————————————————————————————————————————————\nSBP &lt;90          134 (100%)   134 (100%)     132 (100%)  \nDBP &lt;60          72 (53.7%)   83 (61.9%)     78 (59.1%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadvs &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"advs\")\n\n# Output Table\nmake_table_33(advs = advs, alt_counts_df = adsl)\n\n\n\nmake_table_33()\n\nRequired variables:\n\n\nadvs: SAFFL, USUBJID, AVISITN, PARAMCD, AVAL, AVALU, and the variable specified by arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadvs\n(data.frame) Dataset (typically ADVS) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nFALSE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_07.html",
    "href": "quarto/table-templates/template-table_07.html",
    "title": "FDA Table 7",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                  A: Drug X    B: Placebo   C: Combination\nDeaths                             (N=134)      (N=134)        (N=132)    \n——————————————————————————————————————————————————————————————————————————\nTotal deaths                      24 (17.9%)   19 (14.2%)     20 (15.2%)  \n  ADVERSE EVENT                   8 (33.3%)    6 (31.6%)      10 (50.0%)  \n  DISEASE PROGRESSION             8 (33.3%)    5 (26.3%)      6 (30.0%)   \n  LOST TO FOLLOW UP                2 (8.3%)     1 (5.3%)       1 (5.0%)   \n  MISSING                          2 (8.3%)    3 (15.8%)       1 (5.0%)   \n  Post-study reporting of death    1 (4.2%)     1 (5.3%)       1 (5.0%)   \n  SUICIDE                          2 (8.3%)    2 (10.5%)       1 (5.0%)   \n  UNKNOWN                          1 (4.2%)     1 (5.3%)          0       \nTreatment-emergent deaths         12 (9.0%)    15 (11.2%)     16 (12.1%)  \n  ADVERSE EVENT                   3 (25.0%)    5 (33.3%)      9 (56.2%)   \n  DISEASE PROGRESSION             3 (25.0%)    5 (33.3%)      4 (25.0%)   \n  LOST TO FOLLOW UP                1 (8.3%)        0              0       \n  MISSING                         2 (16.7%)     1 (6.7%)       1 (6.2%)   \n  Post-study reporting of death       0         1 (6.7%)       1 (6.2%)   \n  SUICIDE                         2 (16.7%)    2 (13.3%)       1 (6.2%)   \n  UNKNOWN                          1 (8.3%)     1 (6.7%)          0       \nNontreatment-emergent deaths      12 (9.0%)     4 (3.0%)       4 (3.0%)   \n  ADVERSE EVENT                   5 (41.7%)    1 (25.0%)      1 (25.0%)   \n  DISEASE PROGRESSION             5 (41.7%)        0          2 (50.0%)   \n  LOST TO FOLLOW UP                1 (8.3%)    1 (25.0%)      1 (25.0%)   \n  MISSING                             0        2 (50.0%)          0       \n  Post-study reporting of death    1 (8.3%)        0              0       \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Pre-Processing - Ensure all required variables are present in adae\nset.seed(1)\nadae$TRTEMFL &lt;- ifelse(adae$USUBJID %in% sample(adsl$USUBJID, size = as.integer(nrow(adsl) / 3)), \"N\", \"Y\")\n\n# Output Table\nmake_table_07(adae = adae, alt_counts_df = adsl)\n\n\n\nmake_table_07()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, TRTEMFL, DTHFL, DTHCAUS, and the variable specified by arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nTRUE\n\n\nna_level\n(character) String to represent missing values.\n\"MISSING\"\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_32.html",
    "href": "quarto/table-templates/template-table_32.html",
    "title": "FDA Table 32",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\nDiastolic Blood Pressure   A: Drug X    B: Placebo   C: Combination\n(Pa)                        (N=134)      (N=134)        (N=132)    \n———————————————————————————————————————————————————————————————————\n&lt;60                        72 (53.7%)   83 (61.9%)     78 (59.1%)  \n&gt;60                        62 (46.3%)   51 (38.1%)     54 (40.9%)  \n&gt;90                            0            0              0       \n&gt;110                           0            0              0       \n&gt;=120                          0            0              0       \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadvs &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"advs\")\n\n# Output Table\nmake_table_32(advs = advs, alt_counts_df = adsl)\n\n\n\nmake_table_32()\n\nRequired variables:\n\n\nadvs: SAFFL, USUBJID, AVISITN, PARAMCD, AVAL, AVALU, and the variable specified by arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadvs\n(data.frame) Dataset (typically ADVS) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nFALSE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_02.html",
    "href": "quarto/table-templates/template-table_02.html",
    "title": "FDA Table 2",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                                  A: Drug X            B: Placebo         C: Combination      Total Population \nCharacteristic                                     (N=134)              (N=134)              (N=132)              (N=400)      \n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nSex                                                                                                                            \n  F                                                79 (59%)            82 (61.2%)            70 (53%)           231 (57.8%)    \n  M                                                55 (41%)            52 (38.8%)            62 (47%)           169 (42.2%)    \nAge, years                                                                                                                     \n  Mean (SD)                                       33.8 (6.6)           35.4 (7.9)           35.4 (7.7)           34.9 (7.4)    \n  Median (Min - Max)                          33.0 (21.0 - 50.0)   35.0 (21.0 - 62.0)   35.0 (20.0 - 69.0)   34.0 (20.0 - 69.0)\nAge Group, years                                                                                                               \n  &gt;=17 to &lt;65                                     134 (100%)           134 (100%)          131 (99.2%)          399 (99.8%)    \n  &gt;=65                                                0                    0                 1 (0.8%)             1 (0.2%)     \nRace                                                                                                                           \n  ASIAN                                           68 (50.7%)            67 (50%)            73 (55.3%)           208 (52%)     \n  BLACK OR AFRICAN AMERICAN                       31 (23.1%)           28 (20.9%)           32 (24.2%)           91 (22.8%)    \n  WHITE                                           27 (20.1%)           26 (19.4%)           21 (15.9%)           74 (18.5%)    \n  AMERICAN INDIAN OR ALASKA NATIVE                  8 (6%)             11 (8.2%)             6 (4.5%)            25 (6.2%)     \n  MULTIPLE                                            0                 1 (0.7%)                0                 1 (0.2%)     \n  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER           0                 1 (0.7%)                0                 1 (0.2%)     \nEthnicity                                                                                                                      \n  NOT REPORTED                                     6 (4.5%)            10 (7.5%)            11 (8.3%)            27 (6.8%)     \n  HISPANIC OR LATINO                              15 (11.2%)           18 (13.4%)           15 (11.4%)            48 (12%)     \n  NOT HISPANIC OR LATINO                         104 (77.6%)          103 (76.9%)          101 (76.5%)           308 (77%)     \n  UNKNOWN                                          9 (6.7%)             3 (2.2%)             5 (3.8%)            17 (4.2%)     \nCountry of Participation                                                                                                       \n  CHN                                             74 (55.2%)           81 (60.4%)           64 (48.5%)          219 (54.8%)    \n  USA                                             10 (7.5%)            13 (9.7%)            17 (12.9%)            40 (10%)     \n  BRA                                             13 (9.7%)             7 (5.2%)            10 (7.6%)            30 (7.5%)     \n  PAK                                              12 (9%)              9 (6.7%)            10 (7.6%)            31 (7.8%)     \n  NGA                                               8 (6%)              7 (5.2%)            11 (8.3%)            26 (6.5%)     \n  RUS                                              5 (3.7%)              8 (6%)              6 (4.5%)            19 (4.8%)     \n  JPN                                              5 (3.7%)              4 (3%)              9 (6.8%)            18 (4.5%)     \n  GBR                                               4 (3%)              3 (2.2%)             2 (1.5%)             9 (2.2%)     \n  CAN                                              3 (2.2%)             2 (1.5%)             3 (2.3%)              8 (2%)      \nBaseline Temperature (C)                                                                                                       \n  Mean (SD)                                       49.7 (8.3)           50.9 (7.4)           49.1 (8.2)           49.9 (8.0)    \n  Median (Min - Max)                          50.4 (29.0 - 69.1)   51.5 (30.7 - 67.7)   48.7 (20.6 - 70.5)   50.3 (20.6 - 70.5)\n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\nlibrary(dplyr)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadvs &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"advs\")\n\n# Pre-Processing - Add any variables needed in your table to df\nadsl &lt;- adsl %&gt;%\n  dplyr::mutate(AGEGR1 = as.factor(dplyr::case_when(\n    AGE &gt;= 17 & AGE &lt; 65 ~ \"&gt;=17 to &lt;65\",\n    AGE &gt;= 65 ~ \"&gt;=65\",\n    AGE &gt;= 65 & AGE &lt; 75 ~ \"&gt;=65 to &lt;75\",\n    AGE &gt;= 75 ~ \"&gt;=75\"\n  )))\n\nadvs &lt;- advs %&gt;%\n  dplyr::filter(AVISIT == \"BASELINE\", VSTESTCD == \"TEMP\") %&gt;%\n  dplyr::select(\"USUBJID\", \"AVAL\")\n\nanl &lt;- dplyr::left_join(adsl, advs, by = \"USUBJID\")\n\n# Output Table\nmake_table_02(\n  df = anl,\n  vars = c(\"SEX\", \"AGE\", \"AGEGR1\", \"RACE\", \"ETHNIC\", \"COUNTRY\", \"AVAL\"),\n  lbl_vars = c(\n    \"Sex\", \"Age, years\", \"Age Group, years\", \"Race\", \"Ethnicity\",\n    \"Country of Participation\", \"Baseline Temperature (C)\"\n  )\n)\n\n\n\nmake_table_02()\n\nRequired variables:\n\n\ndf: SAFFL and the variables specified by vars and arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\nArgument\nDescription\nDefault\n\n\n\ndf\n(data.frame) Dataset (typically ADSL) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nvars\n(character) Variables from df to include in the table.\nc(\"SEX\", \"AGE\", \"AGEGR1\", \"RACE\", \"ETHNIC\", \"COUNTRY\")\n\n\nlbl_vars\n(character) Labels corresponding to variables in vars to print in the table. Labels should be ordered according to the order of variables in vars.\nformatters::var_labels(df, fill = TRUE)[vars]\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\n\"Total Population\"\n\n\n.stats\n(character) Statistics to include in the table. Includes statistics for all variable types (only the statistics that are valid for a given variable’s type will be printed). See tern::summarize_vars() for options.\nc(\"mean_sd\", \"median_range\", \"count_fraction\")\n\n\n.formats\n(named list of character) List of formats corresponding to each value in .stats. Each name is a value in .stats and the corresponding value is the format that should be applied to that statistic. See formatters::list_valid_format_labels() for a list of valid formats.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nTRUE\n\n\nna_rm\n(flag) Whether NA levels should be removed from the table.\nFALSE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_06.html",
    "href": "quarto/table-templates/template-table_06.html",
    "title": "FDA Table 6",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                                                       A: Drug X    B: Placebo    C: Combination\nEvent                                                                   (N=134)       (N=134)        (N=132)    \n————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nSAE                                                                   104 (85.2%)   101 (82.1%)     99 (82.5%)  \n  SAEs with fatal outcome                                             76 (62.3%)    70 (56.9%)      75 (62.5%)  \n  Life-threatening SAEs                                                9 (7.4%)     13 (10.6%)      19 (15.8%)  \n  SAEs requiring hospitalization                                      24 (19.7%)    28 (22.8%)      29 (24.2%)  \n  SAEs resulting in substantial disruption of normal life functions   28 (23.0%)    21 (17.1%)      23 (19.2%)  \n  Congenital anomaly or birth defect                                  26 (21.3%)    27 (22.0%)      20 (16.7%)  \n  Other                                                               30 (24.6%)    37 (30.1%)      32 (26.7%)  \nAE leading to permanent discontinuation of study drug                 27 (22.1%)    26 (21.1%)      30 (25.0%)  \nAE leading to dose modification of study drug                         71 (58.2%)    86 (69.9%)      83 (69.2%)  \n  AE leading to interruption of study drug                             4 (3.3%)      4 (3.3%)        3 (2.5%)   \n  AE leading to reduction of study drug                               46 (37.7%)    46 (37.4%)      51 (42.5%)  \n  AE leading to dose delay of study drug                              20 (16.4%)    28 (22.8%)      30 (25.0%)  \n  Other                                                               34 (27.9%)    48 (39.0%)      46 (38.3%)  \nAny AE                                                                122 (91.0%)   123 (91.8%)    120 (90.9%)  \n  MILD                                                                 7 (5.2%)      9 (6.7%)        4 (3.0%)   \n  MODERATE                                                            24 (17.9%)    24 (17.9%)      23 (17.4%)  \n  SEVERE                                                              91 (67.9%)    90 (67.2%)      93 (70.5%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Output Table\nmake_table_06(adae = adae, alt_counts_df = adsl)\n\n\n\nmake_table_06()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, TRTEMFL, AESEV, AESER, AESDTH, AESLIFE, AESHOSP, AESDISAB, AESCONG, AESMIE, AEACN, and the variable specified by arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nFALSE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_13.html",
    "href": "quarto/table-templates/template-table_13.html",
    "title": "FDA Table 13",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                      A: Drug X    B: Placebo   C: Combination\nReported Term for the Adverse Event    (N=134)      (N=134)        (N=132)    \n——————————————————————————————————————————————————————————————————————————————\ntrm A.1.1.1.1                         50 (37.3%)   45 (33.6%)     63 (47.7%)  \ntrm B.2.2.3.1                         48 (35.8%)   54 (40.3%)     51 (38.6%)  \ntrm C.2.1.2.1                         35 (26.1%)   48 (35.8%)     55 (41.7%)  \ntrm D.2.1.5.3                         47 (35.1%)   58 (43.3%)     57 (43.2%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Select Preferred Term Variable\nprefterm_var &lt;- \"AETERM\"\n\n# Select Minimum Frequency (%)\nmin_freq &lt;- 0.40\n\n# Output Table\nmake_table_13(adae = adae, alt_counts_df = adsl, pref_var = prefterm_var, min_freq = min_freq)\n\n\n\nmake_table_13()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, and the variables specified by pref_var and arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\nmin_freq\n(proportion) Minimum % frequency (fraction of N) required in any column to include each row.\n0.05\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\npref_var\n(character) Preferred term variable from adae to include in the table.\n\"AETERM\"\n\n\nlbl_pref_var\n(character) Label corresponding to preferred term variable pref_var to print in the table.\nformatters::var_labels(adae, fill = TRUE)[pref_var]\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_20.html",
    "href": "quarto/table-templates/template-table_20.html",
    "title": "FDA Table 20",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                A: Drug X    B: Placebo    C: Combination\nAESI Assessment                  (N=134)       (N=134)        (N=132)    \n—————————————————————————————————————————————————————————————————————————\nAE grouping related to AESI    107 (79.9%)   112 (83.6%)    113 (85.6%)  \n  trm A.1.1.1.1                50 (37.3%)    45 (33.6%)      63 (47.7%)  \n  trm A.1.1.1.2                48 (35.8%)    48 (35.8%)      50 (37.9%)  \n  trm D.1.1.1.1                50 (37.3%)    42 (31.3%)      51 (38.6%)  \n  trm D.1.1.4.2                48 (35.8%)    42 (31.3%)      50 (37.9%)  \n  trm D.2.1.5.3                47 (35.1%)    58 (43.3%)      57 (43.2%)  \nMaximum severity                                                         \n  MILD                         16 (11.9%)    19 (14.2%)      17 (12.9%)  \n  MODERATE                     41 (30.6%)    51 (38.1%)      45 (34.1%)  \n  SEVERE                       50 (37.3%)    42 (31.3%)      51 (38.6%)  \nSerious                        75 (70.1%)    77 (68.8%)      83 (73.5%)  \n  Deaths                       50 (46.7%)    42 (37.5%)      51 (45.1%)  \nResulting in discontinuation   35 (32.7%)    34 (30.4%)      33 (29.2%)  \nRelatedness                    74 (69.2%)    74 (66.1%)      84 (74.3%)  \nLaboratory Assessment          89 (66.4%)    86 (64.2%)      90 (68.2%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Pre-Processing - Add/create any required variables in adae\nset.seed(1)\nadae$AESIFL &lt;- ifelse(adae$AESOC %in% c(\"cl A\", \"cl D\"), \"Y\", \"N\")\nadae$AELABFL &lt;- sample(c(\"Y\", \"N\"), nrow(adae), replace = TRUE)\n\n# Select Preferred Term Variable\npref_var &lt;- \"AETERM\"\n\n# Output Table\nmake_table_20(adae = adae, alt_counts_df = adsl, pref_var = pref_var, aesifl_var = \"AESIFL\", aelabfl_var = \"AELABFL\")\n\n\n\nmake_table_20()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, AEDECOD, AESEV, AESER, AESDTH, EOSSTT, AEREL, and the variables specified by pref_var, aesifl_var, aelabfl_var, and arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\npref_var\n(character) Preferred term variable from adae to include in the table.\n\"AEDECOD\"\n\n\naesifl_var\n(character) Variable from adae that indicates adverse events of special interest.\n\"AESIFL\"\n\n\naelabfl_var\n(character) Variable from adae that indicates a laboratory assessment.\n\"AELABFL\"\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nTRUE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_05.html",
    "href": "quarto/table-templates/template-table_05.html",
    "title": "FDA Table 5",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\n                                           A: Drug X                    B: Placebo                 C: Combination      \nParameter                                   (N=134)                      (N=134)                      (N=132)          \n———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————\nDuration of Treatment, days                                                                                            \n  Mean (SD)                             961.47 (208.61)              949.43 (223.72)              984.69 (200.07)      \n  Median (min - max)               1095.73 (392.78 - 1095.73)   1095.73 (387.34 - 1095.73)   1095.73 (368.90 - 1095.73)\n  Interquartile range                   859.93 - 1095.73             781.55 - 1095.73             960.32 - 1095.73     \n  Total exposure (person years)        105761.39 (289.56)           100639.24 (275.54)           109300.05 (299.25)    \nPatients Treated, by duration                                                                                          \n  Any duration (at least 1 dose)          110 (82.1%)                  106 (79.1%)                  111 (84.1%)        \n  &lt;1 month                                     0                            0                            0             \n  &gt;=1 month                               110 (82.1%)                  106 (79.1%)                  111 (84.1%)        \n  &gt;=3 months                              110 (82.1%)                  106 (79.1%)                  111 (84.1%)        \n  &gt;=6 months                              110 (82.1%)                  106 (79.1%)                  111 (84.1%)        \n  &gt;=12 months                             110 (82.1%)                  106 (79.1%)                  111 (84.1%)        \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\nlibrary(dplyr)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\n\n# Output Table\nmake_table_05(df = adsl)\n\n\n\nmake_table_05()\n\nRequired variables:\n\n\ndf: SAFFL and the variables specified by vars and arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\ndf\n(data.frame) Dataset (typically ADSL) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset used only to calculate column counts.\nNULL\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\nid_var\n(character) Identifier variable used to count the participants within each flag.\n\"USUBJID\"\n\n\ntrtsdtm_var\n(character) Treatment start datetime variable in df.\n\"TRTSDTM\"\n\n\ntrtedtm_var\n(character) Treatment end datetime variable in df.\n\"TRTEDTM\"\n\n\nu_trtdur\n(character) Unit for duration of treatment. Options are \"days\", \"weeks\", \"months\" and \"years\".\n\"days\"\n\n\nlbl_trtdur\n(character) Label for treatment duration variable u_trtdur.\npaste(\"Duration of Treatment,\", u_trtdur)\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nTRUE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/table-templates/template-table_09.html",
    "href": "quarto/table-templates/template-table_09.html",
    "title": "FDA Table 9",
    "section": "",
    "text": "Spec. Screenshot\nTable\nTable Setup\nFunction Details\n\n\n\n\n\n\n\n\n\n\n\nSystem Organ Class                       A: Drug X    B: Placebo    C: Combination\n  Reported Term for the Adverse Event     (N=134)       (N=134)        (N=132)    \n——————————————————————————————————————————————————————————————————————————————————\nAny SAE                                 104 (77.6%)   101 (75.4%)     99 (75.0%)  \ncl A                                    48 (35.8%)    48 (35.8%)      50 (37.9%)  \n  trm A.1.1.1.2                         48 (35.8%)    48 (35.8%)      50 (37.9%)  \ncl B                                    79 (59.0%)    78 (58.2%)      76 (57.6%)  \n  trm B.1.1.1.1                         47 (35.1%)    49 (36.6%)      43 (32.6%)  \n  trm B.2.2.3.1                         48 (35.8%)    54 (40.3%)      51 (38.6%)  \ncl D                                    50 (37.3%)    42 (31.3%)      51 (38.6%)  \n  trm D.1.1.1.1                         50 (37.3%)    42 (31.3%)      51 (38.6%)  \n\n\n\n\n\n# Load Libraries & Data\nlibrary(scda)\nlibrary(falcon)\n\nadsl &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adsl\")\nadae &lt;- scda::synthetic_cdisc_dataset(\"rcd_2022_10_13\", \"adae\")\n\n# Select Preferred Term Variable\nprefterm_var &lt;- \"AETERM\"\n\n# Output Table\nmake_table_09(adae = adae, alt_counts_df = adsl, pref_var = prefterm_var)\n\n\n\nmake_table_09()\n\nRequired variables:\n\n\nadae: SAFFL, USUBJID, AESER, AESOC, and the variables specified by pref_var and arm_var.\n\nalt_counts_df (if specified): SAFFL, USUBJID, and the variable specified by arm_var.\n\n\n\n\n\n\n\n\nArgument\nDescription\nDefault\n\n\n\nadae\n(data.frame) Dataset (typically ADAE) required to build table.\nNo default\n\n\nalt_counts_df\n(character) Alternative dataset (typically ADSL) used only to calculate column counts.\nNULL\n\n\nshow_colcounts\n(flag) Whether column counts should be printed.\nTRUE\n\n\narm_var\n(character) Arm variable used to split table into columns.\n\"ARM\"\n\n\npref_var\n(character) Preferred term variable from adae to include in the table.\n\"AETERM\"\n\n\nlbl_pref_var\n(character) Label corresponding to preferred term variable pref_var to print in the table.\nformatters::var_labels(adae, fill = TRUE)[pref_var]\n\n\nlbl_overall\n(character) If specified, an overall column will be added to the table with the given value as the column label.\nNULL\n\n\nprune_0\n(flag) Whether all-zero rows should be removed from the table.\nTRUE\n\n\nannotations\n(named list of character) List of annotations to add to the table. Valid annotation types are title, subtitles, main_footer, and prov_footer. Each name-value pair should use the annotation type as name and the desired string as value.\nNULL\n\n\n\nSource code for this function is available here."
  },
  {
    "objectID": "quarto/faq.html",
    "href": "quarto/faq.html",
    "title": "Frequently Asked Questions",
    "section": "",
    "text": "1.  How do I install the falcon package?\nFor instructions on installing the falcon package please see the Environment Setup and Package Installation section of the Getting Started page.\n\nMore questions to be added!\n\n\n\n\nOther Questions - Contact Us\nIf you have questions not listed above please contact us by filing an issue on GitHub here or reaching out to the falcon team directly via our Slack channel here."
  },
  {
    "objectID": "NEWS.html",
    "href": "NEWS.html",
    "title": "",
    "section": "",
    "text": "falcon 0.1.0.9026\n\nNew Features\n\nAdded new functions for creating standard FDA tables: make_table_02, make_table_05, make_table_06, make_table_07, make_table_08, make_table_09, make_table_13, make_table_14, make_table_20, make_table_32, make_table_33.\nAdded helper functions used within table functions:\n\nbasic_table_annot for adding basic table annotations (titles, footnotes, column counts).\nsplit_cols_by_arm for splitting columns by arm with option to add total column.\nalt_counts_df_preproc for pre-processing the alt_counts_df dataset.\nassert_flag_variables (internal) for checking that formatting is correct for flag variables in the data.\n\n\n\n\nMiscellaneous\n\nInitialized the package.\nDeveloped Quarto website."
  }
]